Početna › Autoimune bolesti › Iowa
Kliničke studije za Autoimune bolesti u državi Iowa
7 studija za Autoimune bolesti traži sudionike na lokacijama u državi Iowa.
Gradovi u državi Iowa
Službeni tekst studije (engleski)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- The University of Iowa, Iowa City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT06722235A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- University of Iowa, Iowa City
U tijeku regrutacijaFaza 1
Od 18 do 74 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- The University of Iowa, Iowa City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT06948318Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- University of Iowa Hospitals and Clinics, Iowa City
U tijeku regrutacijaFaza 3
Od 18 do 100 godina · Oba spola · Ažurirano 17. kol 2026. · NCT06858319A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- University of Iowa, Iowa City
U tijeku regrutacijaFaza 3
Od 12 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT06056297A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Iowa, Iowa City
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 6. srp 2026. · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- University of Iowa, Iowa City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 29. svi 2026. · NCT04422912Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.